<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Although fecal occult-blood testing is the only available noninvasive screening method that reduces the risk of <z:hpo ids='HP_0011420'>death</z:hpo> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, it has limited sensitivity </plain></SENT>
<SENT sid="1" pm="."><plain>We compared an approach that identifies abnormal DNA in stool samples with the Hemoccult II fecal occult-blood test in average-risk, asymptomatic persons 50 years of age or older </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Eligible subjects submitted one stool specimen for DNA analysis, underwent standard Hemoccult II testing, and then underwent colonoscopy </plain></SENT>
<SENT sid="3" pm="."><plain>Of 5486 subjects enrolled, 4404 completed <z:hpo ids='HP_0000001'>all</z:hpo> aspects of the study </plain></SENT>
<SENT sid="4" pm="."><plain>A subgroup of 2507 subjects was analyzed, including <z:hpo ids='HP_0000001'>all</z:hpo> those with a diagnosis of invasive <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> or advanced <z:mpath ids='MPATH_270'>adenoma</z:mpath> plus randomly chosen subjects with no <z:mpath ids='MPATH_491'>polyps</z:mpath> or minor <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>The fecal DNA panel consisted of 21 mutations </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The fecal DNA panel detected 16 of 31 invasive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, whereas Hemoccult II identified 4 of 31 (51.6 percent vs. 12.9 percent, P=0.003) </plain></SENT>
<SENT sid="7" pm="."><plain>The DNA panel detected 29 of 71 invasive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> plus <z:mpath ids='MPATH_270'>adenomas</z:mpath> with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, whereas Hemoccult II identified 10 of 71 (40.8 percent vs. 14.1 percent, P&lt;0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Among 418 subjects with advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (defined as a tubular <z:mpath ids='MPATH_270'>adenoma</z:mpath> at least 1 cm in diameter, a <z:mpath ids='MPATH_491'>polyp</z:mpath> with a villous histologic appearance, a <z:mpath ids='MPATH_491'>polyp</z:mpath> with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>), the DNA panel was positive in 76 (18.2 percent), whereas Hemoccult II was positive in 45 (10.8 percent) </plain></SENT>
<SENT sid="9" pm="."><plain>Specificity in subjects with negative findings on colonoscopy was 94.4 percent for the fecal DNA panel and 95.2 percent for Hemoccult II </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Although the majority of neoplastic lesions identified by colonoscopy were not detected by either noninvasive test, the multitarget analysis of fecal DNA detected a greater proportion of important colorectal <z:hpo ids='HP_0002664'>neoplasia</z:hpo> than did Hemoccult II without compromising specificity </plain></SENT>
</text></document>